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Abstract
A better understanding of factors associated with early death and survival among children, 
adolescents and young adults with acute myeloid leukaemia (AML) may guide health policy 
aimed at improving outcomes in these patients. We examined trends in early death and survival 
among 3935 patients aged 0 to 39 years with de novo AML in California during 1988–2011 and 
investigated the associations between sociodemographic and selected clinical factors and 
outcomes. Early death declined from 9.7% in 1988–1995 to 7.1% in 2004–2011 (P = 0.062), and 
survival improved substantially over time. However, 5-year survival was still only 50% (95% 
confidence interval 47%–53%) even in the most recent treatment period (2004–2011). Overall, the 
main factors associated with poor outcomes were older age at diagnosis, treatment at hospitals not 
affiliated with National Cancer Institute-designated cancer centres, and black race/ethnicity. For 
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patients diagnosed during 1996–2011, survival was lower among those who lacked health 
insurance compared to those with public or private insurance. We conclude that mortality after 
AML remained strikingly high in California and increased with age. Possible strategies to improve 
outcomes include wider insurance coverage and treatment at specialized cancer centres.
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INTRODUCTION
Acute myeloid leukaemia (AML) is a complex and highly heterogeneous disease. Without 
treatment, most patients die within weeks or months of diagnosis (Appelbaum, et al 2006). 
Survival among patients with AML has increased over the last 3 decades, mostly among 
patients younger than 60 years of age, but progress has now reached a plateau (Pritchard-
Jones, et al 2013; Ribeiro 2014) and acute leukaemias, including AML, remain the leading 
cause of cancer deaths among patients aged 39 years or younger (Deschler and Lubbert 
2006; Wingo, et al 2003). Although complete remission can be achieved in approximately 
75% to 90% of patients younger than 60 years of age, approximately 35% to 50% of these 
patients experience relapse within the following 2 years (Burnett 2005; Hann, et al 2004). 
Disturbingly, children, adolescents and young adults who survive AML may suffer long-
term debilitating complications of treatment, such as secondary malignancies, cardiovascular 
and neurocognitive dysfunctions, as well as severe psychosocial effects (Byrne, et al 2011; 
Dores, et al 2012; Mulrooney, et al 2008; Schultz, et al 2014; Sekeres, et al 2004; Sullivan, 
et al 2013).
Given the lack of population-based studies focusing on young patients with AML (Pulte, et 
al 2009), we aimed to evaluate trends in survival and early death (i.e., death occurring within 
30 days of diagnosis) among patients aged 0 to 39 years with AML in California, and 
investigate sociodemographic and selected clinical factors associated with poor outcomes.
PATIENTS AND METHODS
Patients
Our data were obtained from the California Cancer Registry (CCR), which participates in 
the Survival Epidemiology and End Results (SEER) Programme of the National Cancer 
Institute (NCI). Reporting of all malignant neoplasms is compulsory in California, and the 
standard for completeness of ascertainment is at least 98% (Hayat, et al 2007). In addition to 
relevant variables available in the SEER datasets, the CCR provides information on hospital 
designation (i.e., whether the initial reporting hospital is affiliated with a NCI-designated 
cancer centre), whether the patient has undergone chemotherapy or haematopoietic stem cell 
transplantation (HSCT) and neighbourhood socioeconomic status (SES).
Ethics approval for human subject research was obtained from the Cancer Prevention 
Institute of California Institutional Review Board. As the analysis was based on state-
mandated cancer registry data, the study was conducted in accordance with the waivers of 
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individual informed consent and Health Insurance Portability and Accountability Act 
(HIPAA) authorization.
We identified all patients aged 0 to 39 years who were diagnosed with de novo AML 
between 1 January 1988 and 31 December 2011, and excluded those with acute 
promyelocytic leukaemia, which has a much more favourable prognosis than the other 
subtypes of AML and was the focus of a separate study (Abrahão, et al 2015a). Information 
on patients with AML associated with Down syndrome (who also have a better prognosis) 
was only available in the CCR from 2010 onwards; prior to that, these cases were classified 
as ‘AML not otherwise specified’. Therefore, it was not possible to study these patients 
separately.
To identify cases of AML diagnosed during 1988–2011, we used the following morphology 
codes from the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) 
(World Health Organization 2000): 9840, 9861, 9867, 9870–9874, 9891, 9895–9898, 9910, 
9920, and 9931. We excluded patients diagnosed by autopsy or death certificate only (n = 
12), patients of non-Hispanic American Indian (n = 20) or unknown (n = 18) race/ethnicity 
and patients with a missing month of diagnosis (n = 22). Patients who died on the day of 
diagnosis (n = 28) were included. Of the 4007 patients reviewed, 3935 (98.2%) were 
included in the analyses. All the patients were followed from the date of diagnosis until 
death, loss to follow-up or the end of the study (31 December 2012), whichever occurred 
first.
Demographic and clinical variables
We examined early death and survival with a comprehensive set of variables in order to 
identify the main factors associated with poorer prognosis among young patients (≤ 39 years 
of age). Age is independently associated with survival after AML, and a progressive survival 
decline is observed from 10 years of age (Gatta, et al 2014, Horibe, et al 2001, Ofran and 
Rowe 2014, Razzouk, et al 2006, Walter, et al 2011). Based on these observations, we 
categorized age in 4 groups (0–9, 10–19, 20–29, and 30–39 years). To evaluate trends in 
outcomes, we used 3 calendar periods of diagnosis (1988–1995, 1996–2003, and 2004–
2011). Race/ethnicity was classified in 4 groups [non–Hispanic white (white), non-Hispanic 
black (black), Hispanic, and non-Hispanic Asian/Pacific Islander (Asian)]. Neighbourhood 
SES was divided into quintiles by using a previous developed index (Yost, et al 2001), which 
is based on block-level census data, and is considered an adequate surrogate to SES at the 
individual level (Glaser, et al 2014; Tao, et al 2014). Patients’ health insurance status was 
routinely reported by the CCR from 1996 onwards and was categorized in 4 groups 
[uninsured, publicly insured, privately insured or unknown/not otherwise specified (NOS)]. 
Binary variables were sex (male/female) and initial care at hospitals affiliated with NCI-
designated cancer centres (Y/N).
We provided descriptive information on chemotherapy and HSCT, that, like all treatment 
data collected by the CCR, is limited to the first course of treatment, with no details on 
treatment regimens or intensity. Information on HSCT was routinely reported from 2003 
onwards; however, it was also abstracted for patients diagnosed during 1996–2002, when 
available.
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Statistical analysis
Our analyses investigated how the following variables representing sociodemographic and 
clinical characteristics were associated with early death and overall survival: age at 
diagnosis, treatment period, sex, race/ethnicity, neighbourhood SES, health insurance status, 
and treatment facility. All of the variables considered had a priori hypothesized or previously 
observed (Bradley, et al 2011, Patel, et al 2015a, Percival, et al 2015, Pulte, et al 2013, 
Walter, et al 2011, Wolfson, et al 2012) associations with early death or survival. We also 
hypothesized that sociodemographic factors would have a greater impact on survival in older 
versus younger patients and investigated this hypothesis by analysing the hazard of death by 
age group.
Early death—Chi-squared tests were used for testing whether early death differed among 
groups for each covariate. The Kruskal-Wallis test was also used for ordinal covariates (age 
group, neighbourhood SES and calendar period). We used multivariate logistic regression to 
obtain the odds ratios (ORs) for early death (death within 30 days of diagnosis) and the 
corresponding 95% confidence intervals (95% CIs) associated with sociodemographic and 
clinical characteristics. We used the likelihood ratio test as an overall significance test for the 
association of each independent variable with early death.
Survival—We estimated the overall (all causes) survival at 1, 5, and 10 years by using the 
Kaplan-Meier method and tested differences in survival across strata of each variable with 
the log-rank test (the log-rank test for trend was also estimated for ordinal variables). 
Twenty-eight patients who died on the day of diagnosis were considered to have a survival 
time of 1 day.
The 5-year survival in the 3 calendar periods examined and the 10-year survival in 1988–
1995 and 1996–2003 were estimated using the traditional cohort-based approach, because 
most patients had been followed for at least 5 or 10 years, respectively, during these time 
periods. For patients who had all been followed up for at least 10 years, the classical cohort 
approach provided survival estimates using all the observed follow-up data. For patients with 
less than 5 (or 10) years of follow-up, we used the period approach (Brenner, et al 2004) to 
obtain a short-term prediction of their survival up to 5 (or 10) years after diagnosis on the 
assumption that their partial probabilities of survival will be the same as those observed 
during the most recent years for which follow-up data were available.
We used multivariate Cox regression to obtain the hazard ratios (HRs) and corresponding 
95% CIs for each variable, and the likelihood ratio test as an overall significance test for the 
association of each independent variable with survival. The proportional hazard assumption, 
assessed by looking at Schoenfeld residuals, was met for all variables in the multivariate 
model. To investigate whether the association of survival with sociodemographic and clinical 
factors varied with age, we fitted separate Cox models by age group (0–9, 10–19, 20–29 and 
30–39 years) and tested for interactions between age group and each variable using the 
likelihood ratio test. Statistical analyses were performed using Stata 13 software (StataCorp, 
College Station, TX), and a 2-sided P value of less than 0.05 was considered statistically 
significant.
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RESULTS
Sociodemographic and clinical characteristics
Among 3935 patients, the median age at diagnosis was 23 years (range, 0–39 years), with a 
slight predominance of males (53.5%) (Table I). Most patients were white (41%) or 
Hispanic (39%) and were treated at hospitals that were not affiliated with NCI-designated 
cancer centres (74%). For patients diagnosed during 1996–2011, 85% had health insurance 
(46% had private insurance and 39% had public insurance), 4% were uninsured and 11% 
had unknown or not otherwise specified health insurance status.
Chemotherapy was administered to 93% of patients; it was recommended, but not given, to 
2% of patients, and refused by 0.2% of patients (or their families). A total of 690 patients 
(26%) received HSCT; 324 (27%) of those diagnosed during 1996–2003 and 366 (30%) of 
those diagnosed during 2004–2011. Leukaemia was the cause of death in 88% of patients; a 
small percentage died of other (9%) or unknown (3%) causes. Of the deaths resulting from 
other causes, 3% were caused by infections (data not shown).
Early death
In total, 332 patients (8.4%) died within 30 days of diagnosis. There was a trend towards a 
reduction in early death over time, from 9.7% in 1988–1995 to 8.6% in 1996–2003 to 7.1% 
in 2004–2011 (P = 0.062) (Table I). Overall, in unadjusted analyses, early death was 
strongly associated with age, hospital designation, neighbourhood SES, and health insurance 
status (Table I). In multivariate analyses in which all variates were mutually adjusted (Table 
II). the odds of early death increased progressively with age: the OR for older patients (aged 
30 to 39 years) was increased by 70% relative to that for younger patients (aged 0 to 9 years) 
(OR = 1.70, 95% CI 1.22–2.38). Patients treated at hospitals not affiliated with NCI-
designated cancer centres had a higher risk of early death compared with those treated at 
hospitals affiliated with such centres (OR = 1.75, 95% CI 1.28–2.39). Uninsured patients 
diagnosed during 1996–2011 had an approximately 3 times greater risk of early death than 
privately insured patients (OR = 2.91, 95% CI 1.65–5.12); there was no evidence of such a 
difference between publicly and privately insured patients (P = 0.849). Patients living in the 
lowest SES neighbourhoods had a significantly greater risk of early death than patients 
living in the highest SES neighbourhoods (OR = 1.57, 95% CI 1.05–2.34).
Survival
Of 3935 patients included in the analysis, 2272 (58%) died over the course of follow-up. 
Approximately 93% of patients had confirmation of vital status within 18 months of the 
study end date. The median time to death for deceased patients was 0.9 years, the median 
follow-up time for surviving patients was 8.8 years, and the overall median follow-up time 
using reverse censoring (Schemper and Smith 1996) was 10.0 years. Overall survival 
improved substantially over time for all ages and racial/ethnic groups. Five-year survival 
increased from 32.9% (95% CI 30.3–35.5) in 1988–1995 to 50% (95% CI 47.0–52.9) in 
2004–2011 (Table I). Based on the log-rank test, there was evidence of an association 
between worse survival and older age at diagnosis (Figure 1), black race/ethnicity, receipt of 
initial care in hospitals not affiliated with NCI-designated cancer centres, and, for patients 
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diagnosed during 1996–2011, lack of health insurance. In a multivariate Cox regression 
analysis in which all variables were mutually adjusted (Table III), we found an increased 
hazard of death for older patients compared with younger patients (30 to 39 vs. 0 to 9 years 
of age) (HR = 1.55, 95% CI 1.38–1.74), for black patients compared with white patients 
(HR = 1.27, 95% CI 1.08–1.49), and for patients who received initial care at hospitals not 
affiliated with NCI-designated cancer centres compared with those initially treated at such 
facilities (HR = 1.18, 95% CI 1.07–1.31). For patients diagnosed during 1996–2011, the 
hazard of death was higher among uninsured patients than among privately insured patients 
(HR = 1.34, 95% CI 1.01–1.78), with no evidence of a difference in hazard between 
privately and publicly insured patients (P = 0.429).
When we fitted separate Cox models by age at diagnosis (Tables IV and V), we observed 
that the association between the hazard of death and sociodemographic and clinical factors 
varied by age group. Table IV presents Cox models for the factors available during 1988–
2011 (all variables except health insurance status) by age group at diagnosis. Table V 
additionally includes health insurance status, but is limited to patients diagnosed during 
1996–2011. For patients aged 0 to 9 years, we found no association between the risk of 
death and sociodemographic or clinical factors, whereas associations were found with 
advancing age (Table IV). Markedly, for patients aged 30 to 39 years, the hazard of death 
was substantially higher among those who received initial care at hospitals not affiliated 
with NCI-designated cancer centres (HR = 1.31, 95% CI 1.08–1.58) (Table IV) and, during 
1996–2011, among uninsured patients (HR = 1.78, 95% CI 1.14–2.76) (Table V). We also 
observed an increased risk of death among black patients, particularly those aged 20 to 29 
years (HR = 1.70, 95% CI 1.21–2.39) (Table IV). However, despite observed differences in 
associations between the explanatory variables and survival by age group, none of these 
were found to be statistically significant when tested for interactions between age group and 
each variable, and the results should therefore be interpreted with caution.
DISCUSSION
Our study found evidence of a reduction in early death and an improvement in survival after 
AML over a 25-year period for patients of all age and racial/ethnic groups in California. 
Overall, early death and survival were associated with several sociodemographic and clinical 
factors, including age at diagnosis, race/ethnicity, neighbourhood SES, hospital designation, 
and health insurance status. Despite substantial improvements, approximately half of the 
patients died in the most recent treatment period (2004–2011).
We found worse survival among black patients than white patients, consistent with previous 
studies of AML and acute lymphoblastic leukaemia (ALL) (Abrahão, et al 2015b; Aplenc, et 
al 2006; Byrne, et al 2011; Patel, et al 2015b; Pulte, et al 2012; Pulte, et al 2013; Rubnitz, et 
al 2007; Sekeres, et al 2004). Results from several clinical trials at a single institution in the 
US showed survival in black children with AML to be similar to that in white children 
(Rubnitz, et al 2007). However, a recent trial at the same institution showed a trend towards 
worse outcomes in black children compared to those in white and Hispanic children 
(Rubnitz, et al 2007). It is not yet clear what factors accounted for the disparities in survival 
among black patients with AML that were observed in our and other studies. Black race/
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ethnicity has been associated with both favourable and unfavourable cytogenetic subtypes 
(Rubnitz, et al 2007; Sekeres, et al 2004). It is possible that pharmacogenetic differences 
between black and white patients contribute to different responses to chemotherapy (Pui, et 
al 2004; Rubnitz, et al 2007). Another possibility is that black patients have had less access 
to chemotherapy and/or HSCT. A recent study using CCR data linked to hospital discharge 
data showed that the odds of receipt of HSCT and chemotherapy were lower among black 
than non-black patients (Patel, et al 2015a).
Interestingly, we found no evidence of differences in survival between Hispanic and white 
patients in any age group. This differs from the results of 2 consecutive clinical trials by the 
Children’s Oncology Group (patients aged 0 to 21 years) (Aplenc, et al 2006), but is 
consistent with the population-based study mentioned above (Patel, et al 2015a) that found 
survival among Hispanics to be similar to that among white patients after adjustment for age 
(all ages included), and with paediatric clinical trials that showed favourable outcomes 
among Hispanic patients with AML (Rubnitz, et al 2007). These observations contrast with 
the worse survival observed among Hispanic children and adolescents with ALL in the US 
(Abrahão, et al 2015b; Goggins and Lo 2012; Lim, et al 2014; Pulte, et al 2013), and suggest 
that unfavourable biological characteristics are associated with survival after ALL, (Lim, et 
al 2014) but may not contribute, to the same extent, to the worse outcomes after AML. In 
fact, clinical trials have shown favourable cytogenetic characteristics among Hispanic 
children with AML (Rubnitz, et al 2007).
Clinical (Aplenc, et al 2006) and population-based studies (Patel, et al 2015a) that looked at 
the association of race/ethnicity with survival lacked information on SES. Our information 
on neighbourhood SES found a significant association between lower SES and higher early 
death, but there was no evidence of an association between neighbourhood SES and survival. 
This suggests that some patients with lower neighbourhood SES lacked access to optimal 
treatment during the critical initial days after AML diagnosis.
Our findings showed that survival was better among patients aged 0 to 9 years and there was 
no evidence of increased hazard of death associated with sociodemographic and clinical 
characteristics in this age group. However, among older patients, particularly those aged 30 
to 39 years, we observed an association between increased risk of death and several 
sociodemographic and clinical factors, including treatment at hospitals not affiliated with 
NCI-designated cancer centres, lack of health insurance and black race/ethnicity. The 
diagnosis of AML in older patients may carry a worse prognosis and probably requires more 
intensive chemotherapy and, in some cases, HSCT. Consequently, these patients possibly 
have a higher probability of treatment-related complications (mainly haemorrhage and 
infection) requiring more aggressive treatment and long-term supportive care.
Recent studies have shown that the biology of paediatric AML differs from that of adult 
AML and that structural and numerical chromosome alterations have prognostic 
implications (Grimwade, et al 1998; Harrison, et al 2010; Tarlock and Meshinchi 2015). For 
instance, core-binding factor AML [CBF AML: t(8;21) and inv(16)/t(16;16)], which has a 
favourable prognosis, is more frequent in children and adolescents than in adults. In contrast, 
abnormalities of chromosomes 5 and 7 are more common in adults and are associated with a 
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dismal prognosis (Tarlock and Meshinchi 2015). Additionally, somatic mutations in selected 
genes, such as FLT3, NPM1 and CEBPA, are known to have prognostic clinical significance 
in paediatric and adult AML. Whereas double CEBPA and isolated NPM1 mutations are 
associated with a reduced risk of relapse and better survival (Ho, et al 2009; Yoon, et al 
2015), patients with internal tandem mutations of FLT3 (FLT3-ITD mutations) have a higher 
risk of relapse and worse survival and may benefit from receipt of HSCT (Schlenk, et al 
2008). Adult AML has a higher prevalence of FLT3-ITD mutations compared to paediatric 
AML (27% vs. 12%) (Tarlock and Meshinchi 2015). These cytogenetic and genomic 
differences may partly account for the inferior outcomes we observed among older patients 
and explain the association between worse survival and sociodemographic and clinical 
factors. Hence, interventions to improve timely access to high-quality complex therapy and 
optimal supportive care for all individuals with AML have the potential to reduce mortality 
and morbidity, particularly among higher-risk and minority patients.
Other factors that may contribute to the worse outcomes among older patients with AML 
include the lower participation of adolescents and young adults in clinical trials or treatment 
at hospitals that are not affiliated with NCI-designated cancer centres compared with that of 
paediatric patients (Bleyer and Barr 2009). We had no information on patients’ clinical trial 
enrolment, but our observations support the results from a previous study (Wolfson, et al 
2012) showing that adolescents and young adults with cancer who were treated at hospitals 
affiliated with NCI-designated cancer centres had better outcomes than those treated at 
hospitals not affiliated with such centres.
Moreover, we found evidence of increased early death and worse survival among uninsured 
patients compared to privately or publicly insured patients. These results agree with recent 
studies that showed health insurance status to be independently associated with the risk of 
death (Bradley, et al 2011; Robbins, et al 2014; Rosenberg, et al 2014), and highlight the 
importance of health systems that provide timely access to adequate treatment 
(chemotherapy and, when recommended, HSCT) and optimal supportive care, including 
prophylaxis and control of invasive fungal infection.
Intensive chemotherapy regimens, improvements in supportive care, development of risk-
adapted treatment strategies (through cytogenetic studies and early response to treatment as 
measured by minimal residual disease) and provision of HSCT to a greater number of high-
risk patients are considered the primary causes of better outcomes in AML, rather than novel 
therapeutic agents (Ferrara and Schiffer 2013). Although improvements in HSCT have led to 
a significant decrease in transplant-related morbidity and mortality in patients with AML 
(Ferrara and Schiffer 2013), the role of HSCT remains controversial. With the progress in 
the use of chemotherapy and the improvement in risk assessment over the last 25 years, 
HSCT in first remission is not recommended for AML patients that have a favourable 
prognosis (CBF AML) (Carpenter, et al 2012), and the use of HSCT may be limited to 
intermediate-risk patients who experience relapse after undergoing initial therapy (Burnett, 
et al 2013).
Because AML is a complex disease characterized by morphological and cytogenetic 
heterogeneity, we believe that multiple factors may have contributed to the lower survival we 
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observed among older patients and those of black race/ethnicity. Further improvements in 
disease outcomes will also require the development of more effective and less toxic agents 
for each subtype of the disease (precision medicine) (Rubnitz and Inaba 2012). Conventional 
genetic and, more recently, genomic studies have played a key role in advancing the cure for 
ALL over a period of almost 30 years (Evans, et al 2013), and the same benefit is expected 
for AML. In the new era of basket trials [clinical trial design based on the hypothesis that the 
presence of a molecular marker predicts response to a targeted therapy regardless of tumour 
histology (Redig and Janne 2015)] and big data infrastructure (including access to electronic 
medical records and linkage of cancer registry data with insurance claims information) 
(Meyer and Basch 2015), national and international collaborations are fundamental to help 
to answer questions regarding treatment efficacy, toxicity and long-term survival.
Our study has several limitations. Hospital designation was limited to the location of care at 
the first reporting facility, so it is possible that some patients who were initially treated at 
one type of facility were subsequently treated at another. Nevertheless, the majority of our 
patients (90%) received at least part of their treatment at the reporting hospital. The CCR, 
like the majority of population-based cancer registries, does not collect information on 
patients’ performance status, baseline cytogenetic risk assessment or relapse. Without these 
additional data, it was not possible to clearly investigate whether there was an association 
between the receipt of HSCT and survival. Although supplementary clinical information 
would have contributed additional important findings and explained some of the variability 
of our results, our study provided relevant information on survival and early death over a 25-
year period in the most populous and racial/ethnically diverse state of the United States, 
using high-quality data. We have also provided important information on factors that may 
have influenced AML outcomes. To our knowledge, this is the first population-based study 
to consider the association between neighbourhood SES and outcomes (survival and early 
death) and to identify associations of several sociodemographic and clinical factors with 
survival, both overall and stratified by age group among children, adolescents and young 
adults with AML. Whereas clinical trials are essential to develop guidelines for the best 
therapeutic regimen (better efficacy with less toxicity), they provide data in less than 3% of 
the cancer population (Meyer and Basch 2015), although this proportion is usually higher 
among paediatric patients. In addition, clinical trials commonly report relatively short 
outcomes (i.e., event-free survival and 1 to 5 years overall survival). Our study included up 
to 10 years of survival estimates on virtually all patients in California, important information 
to evaluate long-term outcomes and excess mortality after treatment.
In conclusion, survival after AML increased over time among children, adolescents and 
young adults, but 5-year survival was still only 50% or less in the most recent treatment 
period (2004–2011). We identified subgroups with a higher risk of death from the disease, 
including those aged 10 to 39 years, uninsured patients, those who received initial care at 
hospitals not affiliated with NCI-designated cancer centres and those of black race/ethnicity. 
At the population-based level, strategies to address the high burden of AML, especially 
among adolescents and young adults, may include wider insurance coverage and treatment 
at specialized cancer centres.
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Figure 1. 
Overall survival after acute myeloid leukaemia by age group at diagnosis, in California, 
1988–2011 (percentages in the graph correspond to 10-year survival)
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